☆ 4.6 Article

Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials

BRITISH JOURNAL OF SURGERY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials

Jacob L. van Dam et al.

Summary: This study found that neoadjuvant therapy can improve overall survival in patients with borderline resectable pancreatic cancer. However, more evidence is needed to determine whether it also improves survival in patients with resectable pancreatic cancer.

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Article Oncology

Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial

Eva Versteijne et al.

Summary: This study investigates the impact of neoadjuvant chemoradiotherapy on the survival of patients with resectable and borderline resectable pancreatic cancer. The results demonstrate that neoadjuvant chemoradiotherapy improves overall survival compared to upfront surgery in these patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS)

Atsushi Oba et al.

Summary: The symposium discussed potential modifications to the current resectability classification for pancreatic cancer, with experts from Western and Eastern high-volume centers proposing new classifications based on tumor biology and response to neoadjuvant treatment. Global experts were invited to collaborate on creating an updated, prognosis-based resectability classification.

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2022)

添加到收藏夹

Article Oncology

Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria

Friedrich Anger et al.

Summary: The new definition of borderline resectability for PDAC according to international consensus criteria takes into account anatomical, biological, and conditional dimensions. CA19-9 as an independent prognostic risk factor for OS in BR-B patients.

ANNALS OF SURGICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Cancer Statistics, 2021

Rebecca L. Siegel et al.

Summary: Every year, the American Cancer Society projects the numbers of new cancer cases and deaths in the United States, with the latest data showing a significant decline in lung cancer mortality, while prostate cancer mortality has plateaued and breast and colorectal cancer mortality have slowed. Improvements in treatment have accelerated progress against lung cancer, leading to a record drop in overall cancer mortality.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Review Medicine, General & Internal

Pancreatic Cancer: A Review

Wungki Park et al.

Summary: Pancreatic ductal adenocarcinoma (PDAC) is a relatively uncommon cancer with increasing incidence each year, resulting in a high percentage of patients being diagnosed with advanced disease. Current cytotoxic therapies for PDAC are moderately effective, emphasizing the importance of multidisciplinary management, comprehensive germline testing, and integrated supportive care for all patients.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis

Tara M. Mackay et al.

HPB (2020)

添加到收藏夹

Article Oncology

Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial

Eva Versteijne et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update

Alok A. Khorana et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

T. Conroy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

John P. Neoptolemos et al.

LANCET (2017)

添加到收藏夹

Article Surgery

Postoperative Complications Reduce Adjuvant Chemotherapy Use in Resectable Pancreatic Cancer

Ryan P. Merkow et al.

ANNALS OF SURGERY (2014)

添加到收藏夹

Article Oncology

Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy

Ching-Wei D. Tzeng et al.

ANNALS OF SURGICAL ONCOLOGY (2012)

添加到收藏夹

Article Oncology

Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704

Adam C. Berger et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

添加到收藏夹

Article Surgery

Borderline resectable pancreatic cancer: The importance of this emerging stage of disease

Matthew H. G. Katz et al.

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2008)

添加到收藏夹

Review Oncology

Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer

K. S. Goonetilleke et al.

EJSO (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.